Inflammatory myositis (IM) is a heterogeneous group of autoimmune disorders characterized by immune-mediated muscle injury that results in muscle inflammation and skeletal muscle weakness. Corticosteroids, steroid-sparing agents, and other immunosuppressive drugs are the mainstay for the management of IM. In 2021, Octagam 10% (IVIg) was approved for the treatment of dermatomyositis in the United States and Europe. Targeted assets with novel mechanisms of action (MAb, JAK inhibitor, CTLA-4 agonist, CB2 agonist) are in late-phase development for the treatment of IM. Major unmet needs, including limited approved therapies for IM, present a lucrative commercial opportunity and could drive the future market dynamics.
Executive Insights provides indication-specific market intelligence with world-class epidemiology, keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.
Geography: United States, EU5
Primary research: 13 KOL interviews from November 2021 to January 2022
Key companies covered: Octapharma, BMS, CSL Behring, Corbus Pharmaceuticals, Alexion, Pfizer, Kezar Life Sciences, others
Key drugs covered: Octagam, Orencia, Hizentra, lenabasum, Ultomiris, PF-06823859, KZR-616, others